Bruker files 8-K with Q3 and nine-month 2025 results via Exhibit 99.1

Rhea-AI Filing Summary

Bruker Corporation furnished an update on its financial performance by announcing a press release with results for the three and nine months ended September 30, 2025. The press release, dated November 3, 2025, is provided as Exhibit 99.1.

The company states this information is being furnished under Item 2.02 and is not deemed “filed” for liability purposes, nor incorporated by reference unless expressly stated. The filing also includes a cautionary note regarding forward‑looking statements tied to the press release.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false00011093540001109354us-gaap:CommonStockMember2025-11-032025-11-0300011093542025-11-032025-11-030001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-30833	04-3110160
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation)	File number)	Identification No.)

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

(978) 663-3660

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share		BRKR		The Nasdaq Global Select Market
6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share		BRKRP		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 2 – Financial Information

Item 2.02. Results of Operations and Financial Condition.

On November 3, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained in the press release attached hereto as Exhibit 99.1, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those indicated by these statements. Please refer to the cautionary note contained in the press release under the heading “Forward-Looking Statements” for additional information regarding these forward-looking statements.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits.
	Number		Description
	99.1		Press release dated November 3, 2025.
	104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION (Registrant)
Date: November 3, 2025	By:	/s/ GERALD N. HERMAN
		Gerald N. Herman
		Executive Vice President and Chief Financial Officer

FAQ

What did BRKR disclose in this 8-K?

Bruker announced a press release with financial results for the three and nine months ended September 30, 2025, furnished as Exhibit 99.1.

Which periods are covered by Bruker’s results?

Results are for the three and nine months ended September 30, 2025.

Is the information considered "filed" with the SEC?

No. The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" unless expressly incorporated by reference.

When was the press release issued?

The press release was dated November 3, 2025.

What exhibits are included?

Exhibit 99.1 (press release dated November 3, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Does the filing include forward-looking statements?

Yes. It includes a cautionary note regarding forward-looking statements contained in the press release.

What are Bruker’s trading symbols?

Common stock trades as BRKR, and 6.375% Mandatory Convertible Preferred Stock, Series A, trades as BRKRP on Nasdaq.